Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.50 |
| ▸ | ITGAV | P06756 | 7/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | HRH1 | P35367 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5904218 | 0.85 | HRH3 (0.48) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904186 | 0.84 | HRH3 (0.47) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6833670 | 0.82 | ITGB3 (0.67) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL5904098 | 0.81 | HRH3 (0.55) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904094 | 0.81 | SIGMAR1 (0.55) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904075 | 0.80 | HRH3 (0.60) | HRH3HRH1SIGMAR1BACE1 | |
| SCHEMBL5904276 | 0.80 | HTR1A (0.61) | HRH3HRH1SIGMAR1HTR1A | |
| SCHEMBL5904189 | 0.79 | HRH3 (0.61) | HRH3HRH1SIGMAR1BACE1HTR1A | |
| SCHEMBL5904233 | 0.79 | HRH3 (0.65) | HRH3HRH1BACE1 | |
| SCHEMBL5904191 | 0.79 | HRH3 (0.62) | HRH3HRH1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006046131-A1 | TETRALIN HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-05-04 | — | — | WO | claimed |
| US-20060094719-A1 | Tetralin histamine-3 receptor antagonists | PFIZER INC | 2006-05-04 | — | — | US | claimed |
| WO-2006046131-A1 | TETRALIN HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060094719-A1 | Tetralin histamine-3 receptor antagonists | PFIZER INC | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094719-A1 | Tetralin histamine-3 receptor antagonists | HRH3, HRH4, HRH1 | ITGB3 1564/4885ITGAV 2644/4885ITGA2B 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.